Among the largest conducted studies is the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) study, in which 202,638 healthy average-risk post-menopausal patients (50–74 years) were randomised to receive no screening, annual pelvic ultrasound, or multimodal screening using a combination of CA125 testing (interpreted using risk of ovarian cancer algorithm [ROCA]) and ultrasonography triggered by an increased ROCA score. The gene discussed is MUC16; the disease is ovarian cancer.